Payment overview · 2025
General Payments
$410.79
24 reported records · 7 companies
Healthcare provider profile · identity verified
Avery Jeffers, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PRESTON, ID · NPI 1386083764
Verified facts
What the public records show
CMS Open Payments records show Avery Jeffers, MD received $410.79 in general payments during 2025 across 24 reported records.
ABBVIE INC. accounted for 50.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Qulipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $206.12 | 50.2% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $78.51 | 19.1% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.09 | 8.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.15 | 7.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.13 | 5.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.38 | 5.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.41 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $410.79 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $115.61 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $90.51 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $90.51 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.18 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.09 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.09 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.15 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.18 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 434 | 113 |
| Omeprazole | Omeprazole | 330 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 316 | 85 |
| Gabapentin | Gabapentin | 295 | 77 |
| Potassium Chloride | Potassium Chloride | 271 | 76 |
| Losartan Potassium | Losartan Potassium | 231 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 222 | 67 |
| Furosemide | Furosemide | 208 | 61 |
| Lisinopril | Lisinopril | 187 | 51 |
| Carvedilol | Carvedilol | 145 | 30 |
| Tramadol Hcl | Tramadol Hcl | 136 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 43 |
| Sertraline Hcl | Sertraline Hcl | 127 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 122 | 33 |
| Metformin Hcl | Metformin Hcl | 121 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 42 |
| Celecoxib | Celecoxib | 120 | 32 |
| Metformin Hcl Er | Metformin Hcl | 112 | 32 |
| Lorazepam | Lorazepam | 108 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 25 |
| Trazodone Hcl | Trazodone Hcl | 103 | 23 |
| Xarelto | Rivaroxaban | 103 | 26 |
| Jardiance | Empagliflozin | 99 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 43 |
| Ropinirole Hcl | Ropinirole Hcl | 95 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 89 | 19 |
| Montelukast Sodium | Montelukast Sodium | 88 | 24 |
| Allopurinol | Allopurinol | 87 | 19 |
| Simvastatin | Simvastatin | 86 | 23 |
| Eliquis | Apixaban | 74 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 20 |
| Alprazolam | Alprazolam | 70 | 15 |
| Ozempic | Semaglutide | 66 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 19 |
| Bupropion Xl | Bupropion Hcl | 64 | 14 |
| Clonazepam | Clonazepam | 61 | suppressed |
| Cephalexin | Cephalexin | 57 | 41 |
| Spironolactone | Spironolactone | 55 | 14 |
| Buspirone Hcl | Buspirone Hcl | 52 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 11 |
| Finasteride | Finasteride | 48 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 13 |
| Prednisone | Prednisone | 47 | 39 |
| Ondansetron Odt | Ondansetron | 46 | 25 |
| Azithromycin | Azithromycin | 45 | 37 |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | suppressed |
| Famotidine | Famotidine | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 14 |
| Sucralfate | Sucralfate | 37 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 34 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Meloxicam | Meloxicam | 33 | 12 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 32 | 32 |
| Cefdinir | Cefdinir | 32 | 27 |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 14 |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Estradiol | Estradiol | 28 | 12 |
| Ibuprofen | Ibuprofen | 28 | 12 |
| Trulicity | Dulaglutide | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 15 |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 12 |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Cartia Xt | Diltiazem Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $410.79 · 24 records | ABBVIE INC. | Cologuard Collection Kit, MOUNJARO, Ozempic, QULIPTA, REXULTI, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error